scispace - formally typeset
N

Nancy Y. Ip

Researcher at Hong Kong University of Science and Technology

Publications -  390
Citations -  37404

Nancy Y. Ip is an academic researcher from Hong Kong University of Science and Technology. The author has contributed to research in topics: Cyclin-dependent kinase 5 & Neurotrophin. The author has an hindex of 78, co-authored 381 publications receiving 34323 citations. Previous affiliations of Nancy Y. Ip include University of Cambridge & Chinese Academy of Sciences.

Papers
More filters
Patent

Assay system for degenerative muscle disease

TL;DR: In this paper, an assay system useful for detecting denervated or degenerating muscle by measuring the amount of soluble ciliary neurotrophic factor receptor in body fluids is described, which can be used to detect denervation or degeneration.
Patent

Probes for the detection of rflp in eucaryotic genomes

TL;DR: In this paper, a method for obtaining polynucleotide sequences which are useful for detecting Variable Tandem Repeat polymorphism at multiple genetic loci and other genetic analyses under high stringency conditions (hence, with high specificity) is described.
Patent

Human monoclonal antibodies against epha4 and their use

TL;DR: In this article, the binding properties of human EphA4 monoclonal antibodies with distinct binding characteristics are described, including antigen binding fragments, bispecific forms of these antibodies, and conjugates.
Journal ArticleDOI

A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice

TL;DR: In this paper, the authors used 6-chlorotacrine and the tetrahydroquinolone moiety of huperzine A to design and synthesize a series of heterodimers that inhibit AChE at nanomolar potency.
Patent

Receptor modulators exhibiting neuroprotective and memory enhancing activities

TL;DR: In this paper, the authors provide therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA or MC receptors.